Skip to content
night skyscraper

Closing of MGI Beijing Office

It is with heavy hearts that Mitsui & Co. Global Investment, Inc. (MGI)  announces the closure of our our office in Beijing.  Established 17 years ago, this office worked on identifying start-ups using cutting-edge innovation that would improve human quality of life and also contribute to the local community.  Our team members in China tirelessly interfaced with start-ups, investors and industry professionals at the forefront of innovation in China across a variety of industries including drug development, consumer goods, video, automotive technology and more. 

Two people shaking hands

Beigene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.

Mom holding baby

Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and NeoNatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects.

Back To Top
Search